The estimated Net Worth of Dietrich John Pauls is at least $988 Thousand dollars as of 23 June 2023. Mr Pauls owns over 12,787 units of DiaMedica Therapeutics stock worth over $300,429 and over the last 6 years he sold DMAC stock worth over $0. In addition, he makes $687,579 as Pres and CEO & Director at DiaMedica Therapeutics.
Mr has made over 4 trades of the DiaMedica Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 12,787 units of DMAC stock worth $49,997 on 23 June 2023.
The largest trade he's ever made was buying 12,787 units of DiaMedica Therapeutics stock on 23 June 2023 worth over $49,997. On average, Mr trades about 2,379 units every 165 days since 2018. As of 23 June 2023 he still owns at least 68,591 units of DiaMedica Therapeutics stock.
You can see the complete history of Mr Pauls stock trades at the bottom of the page.
Dietrich John Pauls MBA is the Pres, CEO & Director at DiaMedica Therapeutics.
As the Pres and CEO & Director of DiaMedica Therapeutics, the total compensation of Mr MBA at DiaMedica Therapeutics is $687,579. There are no executives at DiaMedica Therapeutics getting paid more.
Mr MBA is 50, he's been the Pres and CEO & Director of DiaMedica Therapeutics since . There are 5 older and no younger executives at DiaMedica Therapeutics. The oldest executive at DiaMedica Therapeutics Inc. is Dr. Harry W. Alcorn Jr., Pharm.D., 65, who is the Sr. VP of Clinical Operations.
Dietrich's mailing address filed with the SEC is 301 CARLSON PARKWAY, SUITE 210, , MINNEAPOLIS, MN, 55305.
Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg, and David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics executives and other stock owners filed with the SEC include: